Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

141. Should Beta Blockers be Used in Heart Failure with Preserved Ejection Fraction?

Should Beta Blockers be Used in Heart Failure with Preserved Ejection Fraction? Should Beta Blockers be Used in Heart Failure with Preserved Ejection Fraction? | Clinical Correlations Should Beta Blockers be Used in Heart Failure with Preserved Ejection Fraction? August 23, 2017 By Lauren Christene Strazzulla Peer Reviewed The lifetime risk for developing heart failure from age 55 on is 33% for men and 28.5% for women, and as the population ages, there is an increasing [1, 2]. Heart failure is (...) divisible into 2 distinct entities: those with left ventricular systolic dysfunction and those with cardiovascular compromise that does not decrease LV ejection fraction, which is [3]. While these 2 subgroups may present similarly, they develop through different pathophysiological mechanisms. In heart failure with reduced ejection fraction (HFrEF), systolic function is impaired [4]. On the other hand, HFpEF is a heterogeneous and poorly understood condition, and its exact causes remain unclear

Clinical Correlations2017

143. Is it safe to use beta-agonists in patients who have congestive heart failure (CHF)?

Is it safe to use beta-agonists in patients who have congestive heart failure (CHF)? Is it safe to use beta-agonists in patients who have congestive heart failure (CHF)? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Is it safe to use beta-agonists in patients who have congestive heart failure (CHF)? View/ Open Date (...) 2017-07 Format Metadata Abstract Is it safe to use beta-agonists in patients who have congestive heart failure (CHF)? Evidence-based answer: There is concern. Beta-agonist use is associated with a dose-dependent increase in all-cause mortality and heart failure (HF) hospitalization in patients with known HF. Beta-agonist use is also associated with increased vasodilator use and mechanical ventilation in patients admitted for acute decompensated HF (SOR: B, 2 cohort study and 1 case-control study

Evidence Based Practice 2017

144. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. Importance: The natriuretic peptides are biochemical markers of heart failure (HF) severity and predictors of adverse outcomes. Smaller studies have evaluated adjusting HF therapy based on natriuretic peptide levels ("guided therapy") with inconsistent results. Objective: To determine whether an amino (...) -terminal pro-B-type natriuretic peptide (NT-proBNP)-guided treatment strategy improves clinical outcomes vs usual care in high-risk patients with HF and reduced ejection fraction (HFrEF). Design, Settings, and Participants: The Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) study was a randomized multicenter clinical trial conducted between January 16, 2013, and September 20, 2016, at 45 clinical sites in the United States and Canada. This study planned

JAMA2017

145. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model

Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model Journals Library An error occurred retrieving content (...) to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} The efficacy of BNP-guided-therapy in specialist heart failure clinics is uncertain, but if efficacious, it would be cost-effective for patients under 75 with reduced ejection

NIHR HTA programme2017

146. Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial

Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial 28724134 2018 11 13 2380-6591 2 7 2017 Jul 01 JAMA cardiology JAMA Cardiol Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial. 767-774 10.1001/jamacardio (...) collected in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), which randomly assigned 2521 patients to placebo, amiodarone, or ICD between 1997 and 2001. A subset of 1902 participants (75.4%) of the SCD-HeFT had a repeated assessment of EF a mean (SD) of 13.5 (6) months after randomization. We stratified these patients by EF ≤35% and >35% based on the first repeated EF measurement after randomization and compared all-cause mortality in 649 patients randomized to placebo vs 624 patients

JAMA cardiology2017 Full Text: Link to full Text with Trip Pro

147. Declining Risk of Sudden Death in Heart Failure.

Declining Risk of Sudden Death in Heart Failure. BACKGROUND: The risk of sudden death has changed over time among patients with symptomatic heart failure and reduced ejection fraction with the sequential introduction of medications including angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers, beta-blockers, and mineralocorticoid-receptor antagonists. We sought to examine this trend in detail. METHODS: We analyzed data from 40,195 patients who had heart failure with reduced (...) points after randomization and according to the length of time between the diagnosis of heart failure and randomization. RESULTS: Sudden death was reported in 3583 patients. Such patients were older and were more often male, with an ischemic cause of heart failure and worse cardiac function, than those in whom sudden death did not occur. There was a 44% decline in the rate of sudden death across the trials (P=0.03). The cumulative incidence of sudden death at 90 days after randomization was 2.4

NEJM2017

148. Comparative Analysis of Four Scores to Stratify Patients With Heart Failure and Reduced Ejection Fraction

Comparative Analysis of Four Scores to Stratify Patients With Heart Failure and Reduced Ejection Fraction 28629552 2017 06 20 2017 07 09 1879-1913 120 3 2017 Aug 01 The American journal of cardiology Am. J. Cardiol. Comparative Analysis of Four Scores to Stratify Patients With Heart Failure and Reduced Ejection Fraction. 443-449 S0002-9149(17)30783-X 10.1016/j.amjcard.2017.04.047 There are several prognostic risk scores available for patients with heart failure with reduced ejection fraction (...) (HFrEF) that can aid in the decision of listing candidates for heart transplant (HTx). A direct comparison between these scores has not been performed. Therefore, our objective was to evaluate the calibration and discriminative power of 4 contemporary HF scores. A retrospective analysis of 259 patients with HFrEF who underwent cardiopulmonary exercise test was conducted. The Heart Failure Survival Score (HFSS), Seattle Heart Failure Model (SHFM), Meta-analysis Global Group in Chronic Heart Failure

EvidenceUpdates2017

149. Remote management of heart failure using implantable electronic devices

Remote management of heart failure using implantable electronic devices 28575235 2017 06 02 2017 06 02 1522-9645 2017 May 27 European heart journal Eur. Heart J. Remote management of heart failure using implantable electronic devices. 10.1093/eurheartj/ehx227 Remote management of heart failure using implantable electronic devices (REM-HF) aimed to assess the clinical and cost-effectiveness of remote monitoring (RM) of heart failure in patients with cardiac implanted electronic devices (CIEDs (...) ). Between 29 September 2011 and 31 March 2014, we randomly assigned 1650 patients with heart failure and a CIED to active RM or usual care (UC). The active RM pathway included formalized remote follow-up protocols, and UC was standard practice in nine recruiting centres in England. The primary endpoint in the time to event analysis was the 1st event of death from any cause or unplanned hospitalization for cardiovascular reasons. Secondary endpoints included death from any cause, death from

EvidenceUpdates2017

150. Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry

Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry 28432754 2017 04 22 2017 05 31 1463-1326 2017 Apr 21 Diabetes, obesity & metabolism Diabetes Obes Metab Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea (...) : Results from the OsMed Health-DB registry. 10.1111/dom.12979 To re-analyse data from a previous retrospective study on 127 555 patients, in which we showed that dipeptidyl peptidase-4 (DPP-4) inhibitor therapy was associated with a lower risk of hospitalization for HF (HHF) than sulphonylurea (SU) therapy, in order to evaluate intraclass differences among DPP-4 inhibitors and SUs. We included patients with type 2 diabetes (T2D) initiating DPP-4 inhibitor or SU therapy, alone or in combination

EvidenceUpdates2017

151. Effect of Spironolactone on Exercise Tolerance and Arterial Function in Older Adults with Heart Failure with Preserved Ejection Fraction

Effect of Spironolactone on Exercise Tolerance and Arterial Function in Older Adults with Heart Failure with Preserved Ejection Fraction 28542926 2017 05 25 2017 05 25 1532-5415 2017 May 19 Journal of the American Geriatrics Society J Am Geriatr Soc Effect of Spironolactone on Exercise Tolerance and Arterial Function in Older Adults with Heart Failure with Preserved Ejection Fraction. 10.1111/jgs.14940 To evaluate the effects of an aldosterone antagonist on exercise intolerance in older adults (...) with heart failure and preserved ejection fraction (HFpEF). Randomized, placebo-controlled, double-blind trial. Academic medical center, Winston-Salem, North Carolina. Older adults (N = 80, aged 71 ± 1; 80% female) with stable compensated HFpEF and controlled blood pressure (BP). Participants were randomized into a 9-month treatment of spironolactone 25 mg/d vs placebo. Assessments were peak exercise oxygen consumption (VO2 ), 6-minute walk test, Minnesota Living with Heart Failure Questionnaire (MLHFQ

EvidenceUpdates2017

152. Preterm Birth and Risk of Heart Failure Up to Early Adulthood

Preterm Birth and Risk of Heart Failure Up to Early Adulthood 28545637 2017 05 26 2017 05 26 1558-3597 69 21 2017 May 30 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Preterm Birth and Risk of Heart Failure Up to Early Adulthood. 2634-2642 S0735-1097(17)36846-8 10.1016/j.jacc.2017.03.572 In small clinical studies, preterm birth was associated with altered cardiac structure and increased cardiovascular mortality in the young. The goal of this study was to determine (...) the association between preterm birth and risk of incident heart failure (HF) in children and young adults. This register-based cohort study included 2,665,542 individuals born in Sweden from 1987 to 2012 who were followed up from 1 year of age to December 31, 2013. The main study outcome was diagnosis of HF in the National Patient Register or the Cause of Death Register. The association between preterm birth and risk of incident HF was analyzed by using a Poisson regression model. Estimates were adjusted

EvidenceUpdates2017

153. CHA2DS2-VASc Score (Congestive Heart Failure, Hypertension, Age >/=75 [Doubled], Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack [Doubled], Vascular Disease, Age 65-74, Female) for Stroke in Asian Patients With Atrial Fibrillation: A Korean N

CHA2DS2-VASc Score (Congestive Heart Failure, Hypertension, Age >/=75 [Doubled], Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack [Doubled], Vascular Disease, Age 65-74, Female) for Stroke in Asian Patients With Atrial Fibrillation: A Korean N 28455320 2017 04 29 2017 05 23 1524-4628 48 6 2017 Jun Stroke Stroke CHA2DS2-VASc Score (Congestive Heart Failure, Hypertension, Age ≥75 [Doubled], Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack [Doubled], Vascular Disease, Age (...) 65-74, Female) for Stroke in Asian Patients With Atrial Fibrillation: A Korean Nationwide Sample Cohort Study. 1524-1530 10.1161/STROKEAHA.117.016926 The CHA2DS2-VASc stroke score (congestive heart failure, hypertension, age ≥75 (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65-74, female) is used in most guidelines for risk stratification in atrial fibrillation (AF), but most data for this score have been derived in Western populations

EvidenceUpdates2017

155. Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily

Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily 28498942 2017 05 12 2017 05 12 1522-9645 2017 May 12 European heart journal Eur. Heart J. Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily. 10.1093/eurheartj/ehx235 Circulating 25-hydroxyvitamin D (25OHD) levels <75 nmol/L are associated with a nonlinear increase in mortality risk (...) . Such 25OHD levels are common in heart failure (HF). We therefore examined whether oral vitamin D supplementation reduces mortality in patients with advanced HF. Four hundred HF patients with 25OHD levels <75 nmol/L were randomized to receive 4000 IU vitamin D daily or matching placebo for 3 years. Primary endpoint was all-cause mortality. Key secondary outcome measures included hospitalization, resuscitation, mechanical circulatory support (MCS) implant, high urgent listing for heart transplantation

EvidenceUpdates2017

156. Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial

Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial 28531281 2017 05 22 2017 05 22 1522-9645 2017 May 20 European heart journal Eur. Heart J. Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial. 10.1093/eurheartj/ehx259 To determine if an intensified form of heart failure management programme (INT-HF-MP) based on individual (...) profiling is superior to standard management (SM) in reducing health care costs during 12-month follow-up (primary endpoint). A multicentre randomized trial involving 787 patients (full analysis set) discharged from four tertiary hospitals with chronic HF who were randomized to SM (n = 391) or INT-HF-MP (n = 396). Mean age was 74 ± 12 years, 65% had HF with a reduced ejection fraction (31.4 ± 8.9%) and 14% were remote-dwelling. Study groups were well matched. According to Green, Amber, Red Delineation

EvidenceUpdates2017

157. Implications of Alternative Hepatorenal Prognostic Scoring Systems in Acute Heart Failure (from DOSE-AHF and ROSE-AHF)

Implications of Alternative Hepatorenal Prognostic Scoring Systems in Acute Heart Failure (from DOSE-AHF and ROSE-AHF) 28433216 2017 04 23 2017 06 16 1879-1913 119 12 2017 Jun 15 The American journal of cardiology Am. J. Cardiol. Implications of Alternative Hepatorenal Prognostic Scoring Systems in Acute Heart Failure (from DOSE-AHF and ROSE-AHF). 2003-2009 S0002-9149(17)30355-7 10.1016/j.amjcard.2017.03.031 Because hepatic dysfunction is common in patients with heart failure (HF), the Model (...) for End-Stage Liver Disease (MELD) may be attractive for risk stratification. Although alternative scores such as the MELD-XI or MELD-Na may be more appropriate in HF populations, the short-term clinical implications of these in patients with acute heart failure (AHF) are unknown. The MELD-XI and MELD-Na were calculated at baseline in 453 patients with AHF in the DOSE-AHF and ROSE-AHF trials. The correlations and associations for each score with cardiorenal biomarkers, short-term end points at 72

EvidenceUpdates2017

159. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial.

Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. Importance: Iron deficiency is present in approximately 50% of patients with heart failure with reduced left ventricular ejection fraction (HFrEF) and is an independent predictor of reduced functional capacity and mortality. However, the efficacy of inexpensive readily available oral iron supplementation in heart failure (...) is unknown. Objective: To test whether therapy with oral iron improves peak exercise capacity in patients with HFrEF and iron deficiency. Design, Setting, and Participants: Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with HFrEF (<40%) and iron deficiency, defined as a serum ferritin level of 15 to 100 ng/mL or a serum ferritin level of 101 to 299 ng/mL with transferrin saturation of less than 20%. Participants were enrolled between September 2014

JAMA2017

160. Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation

Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation 28359513 2017 03 31 2017 04 06 1558-3597 69 13 2017 Apr 04 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation. 1683-1691 S0735-1097(17)30386-8 10.1016/j.jacc.2017.01.032 The safety and efficacy of aerobic exercise in heart failure (HF) patients with atrial fibrillation (AF) has not been well evaluated. This study (...) examined whether outcomes with exercise training in HF vary according to AF status. HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) randomized 2,331 ambulatory HF patients with ejection fraction ≤35% to exercise training or usual care. We examined clinical characteristics and outcomes (mortality/hospitalization) by baseline AF status (past history of AF or AF on baseline electrocardiogram vs. no AF) using adjusted Cox models and explored an interaction

EvidenceUpdates2017